The global precision medicine market was valued at USD 50.99 billion in 2018 and is projected to reach USD 88.25 billion by 2023, growing at a CAGR of 11.60%. The market is segmented by ecosystem players, therapeutics, and technology, with cancer being the largest therapeutic segment. Key drivers of growth include increasing investments in precision medicine R&D, rising prevalence of chronic diseases, and advancements in technologies such as genomics, big data analytics, and companion diagnostics.

1. Prepared by Netscribes Inc.
Proprietary and Confidential, Copyright © 2018, Netscribes, Inc. All Rights Reserved
The content of this document is confidential and meant for the review of the recipient.
Disclaimer: The names or logos of other companies and products mentioned herein are the trademarks of their respective owners

2. 2
Market scope and segmentation
Globalprecisionmedicinemarket
Segments Types
Based on therapeutics
Based on regions
Pharmaceuticals and biotech companies
Clinical laboratories
North America Europe Asia-Pacific
Latin America The Middle East and Africa
Based on ecosystem players
Based on technology
Diagnostic companies
Healthcare IT/big data companies
Cancer
Cardiovascular diseases
Central nervous system (CNS)
disorders
Infectious diseases
Psychiatric disorders
Big data analytics
Bioinformatics
Genomics
Pharmacogenomics
(drug discovery)
Companion diagnostics
Epigenetics
Respiratory diseases
Others
Others

3. 3
Executive summary
Overview
Trends
• The global precision medicine market is projected to expand at a compound annual growth rate (CAGR) of 11.60%, owing to the early diagnosis of
diseases, and a rise in the rate of chronic disorders, among others.
• The global precision medicine market accounted for USD 50.99 Bn in 2018 and is estimated to reach USD 88.25 Bn by 2023.
• New technologies like gene therapy, molecular biomarker analysis, genome sequencing, and companion diagnostics are helping in creating
personalized medicines for providing better treatment.
• Increase in investments in precision medicine research and development (R&D) by the major players across the world have also fueled the
growth of the precision medicine market in the world.
• Increase in cases of cancer, high prevalence of chronic diseases, and growth of adverse drug reaction (ADR) instances worldwide have driven
the market in various regions.
• Advancement in big data, private and public cloud platforms, and use of predictive analytics in the healthcare sector, particularly in dealing
with chronic diseases, have helped in the growth of the market.
• Changing government regulations related to healthcare and medication can also be considered to be propelling market growth.
• Nanomedicine, the application of nanotechnology to healthcare, has the potential to change disease management and its results, based on
targeted drug delivery and enhanced molecular imaging, thus reducing adverse side effects.
• With the latest advancements in gene therapy, next-gene sequencing (NGS) can help achieve the goals of precision medicine, where
segments of the population can be targeted in terms of disease susceptibility or drug toxicity.
• NGS allows to link common clinical phenotypic data with genotypic information. It has proved to be a beneficial tool for diagnosis and
disease management. The integration of NGS with in vitro diagnostic procedures can generate huge clinically relevant data.
• Personal genomic information, and exome sequencing for individual genetic variants are paving novel therapeutic strategies for diagnostics
and treatment of diseases.
• Developing accurate precision medicine solutions and making it available for the consumers at affordable prices can restrict the growth of the market.
• Security of personal data, which is available in abundance, can be at stake in the healthcare sector.
• Medical infrastructure across the regions cannot be uniform, and thus the developing regions find it challenging for the growth of the precision medicine
market.
• Further, the approval of certain drugs and therapies from the regulatory bodies can hamper market growth in the region.
USD Bn
XX.XX
XX.XX
88.25
2015 2018 2023

4. 4
Market definitions
Precision medicine, also known as personalized medicine, consists of approaches for protecting health and treating diseases by taking into account a person’s genetic makeup, behaviors, and
environment. The global precision medicine market can be segmented based on ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, and
healthcare IT /big data companies), therapeutics (cancer, cardiovascular diseases, CNS disorders, psychiatric disorders, respiratory diseases, infectious diseases, and others) and technology (big
data analytics, bioinformatics, genomics, epigenetics, pharmacogenomics, companion diagnostics, and others).
Based on ecosystem players
• Pharmaceuticals and biotech companies: Pharmaceutical and biotech companies develop, manufacture, and market drugs based on the biomarker
drug label identified in the compounds during clinical trials, thereby categorizing different precision medicine drugs for different targeted therapies.
• Clinical laboratories: Clinical labs play a unique role by serving as the conduit and interpreter of data-enriched biospecimens. They facilitate an
enhanced understanding of clinical pathways as well as treatment paradigms, thereby suggesting proper treatment.
• Diagnostic companies: Diagnostic companies have been increasing their investment in biomarkers that focus on infectious diseases, CNS conditions,
and cardiovascular diseases to widen the overall research and diagnostic strategies.
• Healthcare IT/big data companies: Big data/IT companies will be driving the market further by creating a database and analyzing it for better
solutions, and helping in giving prescriptions tailored according to patients.
Based on therapeutic areas
• Cancer: The cancer segment is expected to grow rapidly owing to the increasing prevalence of cancer, globally, especially breast and lung cancer. Precision medicine helps physicians determine cancer treatments
that will be more effective for patients based on the genetic understanding of their tumor cells.
• Cardiovascular diseases: Precision medicine is an integrative approach to cardiovascular disease prevention and treatment that considers an individual’s genetics and lifestyle as determinants of their
cardiovascular health and disease phenotypes.
• CNS disorders: Disorders like multiple sclerosis and Parkinson’s disease, which varies according to individuals and their genetics, are usually addressed by precision medicine solutions.
• Psychiatric disorders: Precision medicine is used in order to better understand cerebral networks for the prevention and cure of psychiatric disorders.
• Infectious diseases: Antibacterial agents help in the development of medication and treatment for infectious diseases like tuberculosis, meningitis, hepatitis, etc. Customized and affordable molecular
technologies are used in the diagnosis, treatment, and control of infections. Precision medicine helps in combining technologies to enhance public health surveillance, investigations and control of infectious
diseases.
• Respiratory disease: Precision medicine has emerged as a medical care approach to treat asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and other respiratory diseases.
• Others: This includes disorders pertaining to skin, eyes, and many others.
Based on technology
• Big data analytics: Developments of data mining algorithms and big data is expected to provide insight into health, and state of diseases, which can be transformed into personalized disease prevention and
treatment plans.
• Bioinformatics: It is a cross science that associates biological data with methods for storing information, distribution, and analysis to support manifold areas of scientific research, including biomedicine.
• Genomics: It is an important driver in precision medicine which has helped in improving the landscape of cancer diagnosis and differential diagnosis of single gene diseases.
• Pharmacogenomics: It deals with the use of gene information to categorize drug selection. Moreover, it is essential for evading any adverse effects of drugs on patients, and also for increasing their efficiency,
thereby helping the drug development process.
• Epigenetics: Epigenetic tests play an important role in making precision medicine a clinical reality. It helps in risk assessment and determines how diseased cells react to a drug treatment.
• Companion diagnostics: Companion diagnostics are medical devices that help doctors decide the course of treatments, and dosage for individual cases.
• Others: This includes technologies such as 3D printing, molecular diagnostics, etc.

5. Value chain – precision medicine
5
Purchasers
Manufacturers
Regulatory
bodies
Hospitals/physicians
Traditional
prescription
medicines
Precise diagnostic
tools/firms
Different diagnostic tools/technologies like companion diagnostics, panomic analysis,
system biology, pharmacogenomics, oncotype Dx, gene detection, molecular imaging
technologies, etc. are implemented to classify people into categories according to their
susceptibility to a particular disease or response to a particular drug. With the help of this
data, a targeted treatment or therapy, that can specifically treat the targeted sub-
category of patients, can be developed.
Decision of targeted
treatment/ therapy
by physician
Targeted
precision
medicine
YES
In the precision medicine value chain, diagnostics and categorization of
patients have a paramount role in custom designing and implementation
of medicine for every individual.
• Wholesalers
• Group purchasing
organizations
• Distributers
Links common to both traditional
medicine as well as precision medicine
Links to traditional medicine
Links to precision medicine
Traditional medicine follows a one-size-fits-all approach. Large groups of people
suffering from the same disorder are treated using the same drugs and therapies.
Scientists develop and test drugs through clinical trials to treat the symptoms of a
disease or the disease itself.

6. 6
Global precision medicine market - overview
Precision medicine involves the treatment of patients based on their genetic makeup, lifestyle, and environment. The global precision medicine market is forecasted to expand at a CAGR of
11.60% and reach USD 88.25 Bn by 2023, from USD 50.99 Bn in 2018. The cancer segment dominated the market with a share of 30%-35%. Genomics, followed by big data analytics have the
highest growth rates.
XX.XX
XX.XX
XX.XX
2015 2016 2017
XX.XX
XX.XX
XX.XX
XX.XX
XX.XX
88.25
2018 2019 2020 2021 2022 2023
Global historical market revenue (USD Bn) Global forecasted market revenue (USD Bn)
CAGR (2015-2017): XX.XX% CAGR (2018-2023): 11.60%
Key observations
• Increase in efforts to identify and evaluate genes in individuals, and the increasing demand for customized treatments are the major factors which are going to help in the growth of the precision
medicine market, globally.
• The sale in the global precision medicine market is expected to increase, owing to advancement in the field of cancer biology, and by improving the technologies involved in the diagnosis of a particular
disease and its after-effects.
• The Food and Drug Administration (FDA) approved 16 new precision medicine therapies in 2017 because of increase in demand for customized drugs and therapies in the market.
• NGS-based genomic data have been explored to better understand disease development and patient characteristics that impact the response to a particular therapeutic intervention.
• NGS-based technologies can track how diseases aggravate and their resistance to treatment, which are essential in the development of next-generation disease diagnostics.

7. XX.XX
22.01
XX.XX
2015 2018 2023
North America
XX.XX
XX.XX
XX.XX
2015 2018 2023
Europe
7.57
XX.X
X
XX.X
X
2015 2018 2023
Asia-Pacific
XX.X
X
XX.X
X
XX.XX
2015 2018 2023
Latin America
XX.X
X
XX.X
X
XX.X
X
2015 2018 2023
The Middle East and Africa
Global precision medicine market - geographic overview
7

8. 8
Integrating genetic
testing with cancer
diagnosis
Improve
standardization
and validation of
“dry lab”
capabilities
Integrating
therapeutics and
diagnostics
Role of IoMT
(Internet of Medical
Things) in
healthcare
Integrating genetic testing with cancer diagnosis: Later-
stage melanoma, colorectal, and lung cancer patients are
usually given DNA-based molecular diagnostic and
prognostic tests. Similar to molecular diagnostic testing, a
number of medical institutions are trying to develop in-
house testing capabilities. QIAGEN Clinical Insight (QCI), an
artificial intelligence (AI) genomics solution, allows
molecular diagnostic labs and healthcare providers to
expand and secure molecular and genomic data analysis,
interpretation, and maintain records to implement
genomics-guided clinical decision.
Improving standardization and validation of ‘dry lab’
capabilities: Sunquest Mitogen helps labs to standardize and
streamline NGS testing and analysis for actionable clinical
reporting and molecular diagnostics. Extensive adoption of
such guidelines will enhance communication among
molecular pathologists, oncologists and geneticists, and will
aid enhance patient care. QCI helps with the standardization
of NGS analytical workflows by helping clinical testing
laboratories develop and implement a production pipeline for
patients.
Role of IoMT in healthcare: With the rise of IoMT,
mobile and wearable devices make medical
information accessible to healthcare professional,
remotely. This data can be used to detect the risk
factors and offer preventive treatment to the
patients. Mobility and cloud access will help
patients and doctors interact better in real time. AI
will help healthcare specialists in drawing out data
to recognize the risk factors for providing effective
clinical treatment.
Integrating therapeutics and diagnostics:
Integration of therapeutics and diagnostics to
develop personalized treatments is being
emphasized upon. Due to the increased demand
for personalized medicine, theranostics is expected
to grow in the coming years. Thus, we see
variability in targeted therapy. The QCI platform is
a tool that evaluates genomic samples by
comparing them with published biomedical
literature, professional association guidelines,
publicly available databases, drug labels and clinical
trials. With QCI, clinicians will be able to quickly
classify variations and identify treatment options.
Global precision medicine market – trends

9. 9
New technologies: Precision medicine is a relatively new concept. The
technologies used to meet the objectives of precision medicine are either at the
very early stages of development or haven’t yet been developed. For this,
methods for the standardization of data are crucial. Researchers need to design
databases for storing large amounts of patient data. Technologies like gene
therapy in precision medicine for treating cancer also needs to be developed for
its better performance.
Cost: The technologies involved in determining disorders, and developing
precision medicines are expensive. Reimbursements from third-party
payers for the targeted drugs and therapies can also be one of the
challenges. For example, in technologies like gene sequencing, sequencing
large amounts of DNA is expensive to carry out.
Threat to personal data: The precision medicine initiative (PMI) is a long-term
research endeavor that also raises moral, communal, and legal issues. It will be
difficult to find ways to protect patients’ privacy and confidentiality of their health
information. Designing databases to store large amounts of patient data efficiently
is difficult. An unsecure database is a threat to patients’ personal information.
Lack of disease signatures: Cancer, neurological disorders and other rare
diseases can be treated more effectively if the disease cell signatures are
identified at an early stage. The change of genetic signatures over time
will result in not identifying the signatures appropriately. Nature of the
genetic signatures pose a challenge for the applications of precision
medicine.
Lack of access: Although there is a huge potential for genetics and genomics in
precision medicine, ranging from accelerating diagnosis to treatment of chronic
diseases, as well as reduction in the cost of care, the biggest challenge is the lack
of access either to resources, such as genetic counselors, geneticists, and
certified genetic nurses, or to education and experience.
Global precision medicine market – challenges

10. Key observations
The cancer therapeutics segment is expected to expand at a CAGR of 12.98% during 2018-2023,
thereby increasing the revenue. The United States (U.S.) FDA and the European Union (EU) have
undertaken significant initiatives to fuel the growth of the global oncology/cancer drugs market by
providing pre-market approval for potential drugs under clinical development.
12.21 XX.XX XX.XX
XX.XX
XX.XX
XX.XX
XX.XX
XX.XX
XX.XX
2015 2016 2017 2018 2019 2020 2021 2022 2023
Cancer - revenue contribution (USD Bn)
CAGR (2018-2023): XX.XX%
10
Cancer therapeutics is primarily driven by huge research investments, and is
expected to be the largest revenue generating segment. Targeted cancer
therapies have gained much importance, owing to their cell-specific actions,
without affecting healthy cells. Syapse, Inc., a precision medicine solution
company, has raised USD 30 Mn in Series D financing, which will enable most of
the providers to use precision medicine for cancer patients.
Cancer is deemed to be the second leading cause of death, worldwide. Treatment for cancer can
be customized as per the patient’s genetic makeup, and the number of cancer cells present.
Advancement in biological therapies has broadened the scale of therapeutic targets for treating
cancer with the identification of tumour cell-specific genes.
Global precision medicine market – cancer
Precision medicine for cancer emphases on matching the most appropriate and
effective treatment for each individual patient, based on the severity of the
disease and the genetic profile of the individual. Since every single cancer patient
exhibits a different genetic profile and it can change over time, more patients will
benefit if therapeutic options can be personalized for each individual.

11. North America precision medicine market
Drivers
Trends
Revenue contribution (USD Bn)
CAGR (2018-2023): 11.00 %
• The maximum share of North America is attributed to factors like increasing federal
healthcare mandates, to trigger rising healthcare costs and provide quality care.
• As health systems merge and acquire new hospitals and institutions, a growing number of
electronic medical reports (EMRs), electronic health record (EHRs) and health information
exchanges (HIEs), that cover a significant number of patients, are becoming
interconnected.
• In 2015, President Obama announced the launch of PMI for aggressive research in
personalized medicine, and improve treatment processes. Therefore, due to such
governmental initiatives and regulations in the region, the market has experienced a
growth, and is also expected to expand in the forecast period of 2018-2023.
• The estimated national expenditure for cancer care in the U.S. in 2017 was USD 147.3 Bn.
Thus, prevalence of cancer and other rare diseases are driving the growth of this market.
• Increasing federal healthcare mandates to control the soaring cost of healthcare, and
provide quality care, rising regulatory requirements, and growing EHR adoption are the
factors expected to drive the market growth.
Challenges
• Technology giants, Google and Microsoft, are investing over USD 50 Bn in startup
companies like DNAnexus, which aims to leverage its footprint in genomic data
management for clinical trials through this funding.
• Genome Canada, the Canadian Institute of Health Research, and several other institutes
collectively invested USD 256 Mn for the advancement of sequencing and genomic
technologies in making precision medicine accessible to patients in Canada.
• The National Institute of Health (NIH) in the U.S. has come up with a program, known as
All of Us, which focuses on gathering genetic, biological, environmental, health and
lifestyle data from people living in the U.S. to improve healthcare provisions in precision
medicine.
• The regulatory landscape of precision medicine is still in an infant stage in the
U.S. Acquiring approvals required by pharmaceutical companies from the U.S.
FDA for a particular drug or treatment is a time consuming procedure due to
the uncertainties involved, and thus it can hinder the growth of the precision
medicine market.
• Patients can be treated more effectively once the disease cell signatures are
identified. One of the challenges in recognizing these signatures, is the
change of these cell signatures over time.
• Privacy and security of the data is another barrier in the precision medicine
market because of the huge number of healthcare datasets.
XX.XX XX.XX XX.XX
22.01 XX.XX
XX.XX
XX.XX
XX.XX
XX.XX
2015 2016 2017 2018 2019 2020 2021 2022 2023
11

12. 12
Pfizer is a pharmaceutical company, set up in 1849 in New York City. It is known for the drugs Advil and ChapStick. It acquired Wyeth in order to improve its R&D
process.
• Pharmaceuticals
• Vaccines
• Consumer healthcare
Company snapshot
Product/services
Company Overview – Pfizer
 Pfizer launched its Center of Excellence in Precision Medicine
(CEPM) in Chile, investing an amount of USD 14 Mn in the
initiative. It focuses on validating new, more precise and less
invasive technologies for diagnosing lung cancer, and place Chile
on the map of innovation centers at a regional and global level.
 Pfizer is also a member of the Worldwide Innovative Network
(WIN) in personalized cancer medicine consortium. The WIN
Consortium is an international network of academic, industry,
and patient advocacy organizations whose aim is to curate
precision medicine and tailored treatments for cancer patients
worldwide. WIN is headquartered in Paris.
 Pfizer collaborated with IBM to launch the Blue Sky project,
which aims to develop technologies such as internet-connected
motion sensors and devices to monitor patients at their homes
and upload the information in real time. The technologies are
being tested with Parkinson’s patients, with the view that the
continuous data series could allow researchers to track the
effectiveness of treatment, and trace the relevant variation in
those responses.
Major initiatives/highlights
Founded: 1849
Headquarters: New York City, New York, U.S.
Key people: Ian Read (Chairman and Chief
Executive Officer )
Employees: 90,200
Revenue: USD 52,546 Bn (2017)
Website: www.pfizer.com
Growth strategy
Pfizer collaborated with Medco for research on precision
medicine. The partnership is expected to improve Pfizer’s
precision medicine approach, which integrates genomic and
phenotypic data, to help recognize the underlying biology of
disease, and identify patients likely to benefit from a new drug.
Pfizer and Merck & Company invested around USD 26 Mn in the
precision medicine start-up, Strata Oncology. Strata Oncology is
dedicated to transforming cancer care by systematizing precision
oncology across a network of health systems and pharmaceutical
companies.
Global presence
• North America
• Latin America
• Europe
• Asia
• The Middle East and Africa
Note: *Revenue figure indicates the total revenue of the company.

13. Appendix
13
Research methodology
The study begins with identifying the right research question(s). The question depends on what we are going to achieve by conducting the research or what we want
to convey to the prospective customers through this research. Next we identify the logical steps to arrive at the answers to the question(s). These logical steps form
our research objectives. The research objectives provide us a guideline regarding what information we need to conduct analysis. We strongly believe that clear
objectives will lead to clear results about the given market
The next stage of the research is conducted utilizing the secondary sources of information, process called desk/secondary research. Netscribes Inc. has a considerable
volume of information in both quantitative and qualitative forms, across all major industries and its sectors. Also, we conduct in-depth study of the market,
understanding its key stakeholders, drivers, trends, challenges and opportunities globally covering major regions such as North America, Latin America, Europe, Asia
Pacific, and the Middle East and Africa. The key sources consumed for these research include (but not limited to) the following:
 Financial reports published by the key market players
 Government and other official sources including the National Statistics
 National and International trade associations
 Paid databases
 Other reliable sources
The qualitative and quantitative findings from the above stages are brought together by specialists to perform a rigorous analysis. The regional market trends, drivers,
and opportunities obtained during the analysis is compared with regional economic indicators, sector growth rates, population index, etc. to ensure the data
consistency. After ensuring the consistency, these historical and present indicators help us to understand how the market will perform in future. Our proprietary
forecasting model factors in all these indicators to predict the future market accurately.
Primary research complements the secondary research, as and when required, as it helps us to gain insights from the industries directly by communicating with the
senior executives, key opinion leaders and independent consultants who are experts in their industries or specific industry sectors. Such interviews are conducted
across the value chain of the market in question. A survey questionnaire is usually prepared for conducting any primary interview or survey. The questionnaire is
developed with utmost care to fulfil the key research objectives and also to validate the assumptions about the market. This supplements the information otherwise
unaddressed via secondary research. The primary data collection is done by expert interviewers who have specific industry knowledge. Linguists are hired to conduct
interviews in the respondent’s native language. Some of the primary research methods applied at Netscribes include the following:
 In-depth Interviews
 Executive Interviews
 Expert Panels

14. Appendix
14
About Netscribes Inc.
MBA
28%
Graduates
22%
BE
20%
BCA/MCA
12%
CPA/CA/CFA
8%
Others
10%
Multidisciplinary Team
Netscribes provides end-to-end research-driven solutions that help clients meet their growth objectives by collaboratively transforming information into business advantage.
In-house Research Data VisualizationGlobal CoveragePanel Expertise Premium Databases
We utilize an in-house
resource model to provide
our clients with actionable
insights
Specialized panel of senior
executives, analysts and
practitioners
Extensive experience of
working on various premium
databases
Ability to conduct research
across the globe in multiple
languages
Ability to present complex
data insights in crisp, easy-to-
understand visuals
Global market
intelligence and
content services
provider
Venture-funded by US
based private
equity firm Helix
700+ member delivery
team across Mumbai,
Kolkata and Gurgaon,
and sales presence in
Singapore and the USA
Revenue composition:
USA: 50%
Europe/MENA: 30%
APAC: 20%
Official ESOMAR
member
Owns:
– Inrea Research
– OnSense
– Research on
Global Markets

15. 15